Daily IPO Digest
Daily Digest — October 17, 2026
Published
Not financial or investment advice, and not a solicitation to buy or sell any security or to use our service. This is AI-assisted analysis of public SEC filings, provided for informational purposes only.
Figures are drawn from those filings and checked against them; any interpretation, conclusion or forecast is our analytical opinion rather than a statement of fact. We do not intend to defame any person or entity.
It is generated by an automated pipeline with no human review and will likely contain factual errors, interpretive errors, and errors of omission that misrepresent the business or the offering — none of them intentional. Do not rely on it as the sole basis for any investment decision. Always do your own research.
Hit the market today
City Therapeutics (CTY)
CTY · Priced · RNA therapeutics · Nasdaq
City Therapeutics priced at $18.00 per share, selling 11,111,111 shares for net proceeds of $181.5 million — rising to $209.4 million if underwriters exercise the 30-day greenshoe on 1,666,666 additional shares. Founded in 2023, the company is an siRNA platform built by a team that contributed to 7 of the 8 FDA-approved RNAi therapeutics currently on the market — that lineage is the core credentialing claim, and it is specific enough to take seriously.
The proceeds allocation is the tell. The largest single bucket — $70 million — goes to the City Platform itself, not to any clinical program. CITY-TFR2, an anemia target not yet in Phase 1, gets $40 million. CITY-FXI, the only asset with human data — three Phase 1 cohorts completed, dose-dependent FXI knockdown of 60% to 85% across the dose range — gets $30 million. Capital is flowing in near-perfect inverse order of clinical maturity. Cash runway extends to 2028 on an accumulated deficit of $142.5 million. The full brief is linked above.
Just filed
Talyxor Corp
No ticker · Initial S-1 · Travel/logistics SaaS · Terms not yet set
Talyxor filed an S-1 to sell 5,000,000 shares at $0.06 each — a self-underwritten offering with no placement agent, seeking to raise up to $300,000 at an implied market cap of $420,000. Founded in 2026, the company has no revenue, no cash, and no employees. Its sole asset is a website under development, capitalized at $19,000, with $16,000 still owed to the developer. The working capital deficit stands at $17,714.
The filing describes a planned SaaS platform for travel and transportation logistics, with tiered monthly pricing from $299 to $2,499 once operational — but nothing is operational yet. The offering runs for up to 240 days with no stated minimum close threshold. The founder paid $0.004 per share for the 2,000,000 founder shares; new investors are asked in at a price many multiples higher. Pre-revenue, pre-product, pre-staff — this is a registration, not a company in the conventional sense.
Sources
Regulatory filings
- SEC filings
Some figures are computed from the source material above.